Home

SUNIL AGARWAL

CIK 1616640 · EVP, Head of Development & CMO · last filed 2026-01-23

SUNIL AGARWAL is an EVP, Head of Development & CMO who has filed 53 SEC Form 4 insider transactions across 7 companies since 2014. The most recent filing, for ATXS, was dated Jan 23, 2026. Across all open-market trades the lifetime net is −$4.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.4M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.41M

Companies

7

Total Filings

53

Lifetime Open-Market Net

-$4.28M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Astria Therapeutics, Inc. (ATXS) Delisted Director — $12.58 — $0 3 2026-01-23
ARVN Director 30,166 $8.06 $243.1K $0 3 2025-06-30
Calithera Biosciences, Inc. (CALA) Delisted Director — $0.00 — $0 8 2022-06-03
SANA EVP, Head of Development & CMO 1,551,627 $3.18 $4.93M -$1.56M 4 2022-03-08
MyoKardia, Inc. (MYOK) Delisted Director 2,300 — — $0 8 2020-06-23
Juno Therapeutics, Inc. (JUNO) Delisted President of R & D 35,893 — — -$326.1K 5 2018-03-07
RARE Chief Medical Officer 9,136 $25.02 $228.6K -$2.39M 21 2016-08-23

Recent Filings

53 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-01-23 Astria Therapeutics, Inc. (ATXS) Delisted Disp (D) — $0 EDGAR
2025-06-30 ARVN Grant (A) +16,025 $0 EDGAR
2025-06-12 Astria Therapeutics, Inc. (ATXS) Delisted Grant (A) — $0 EDGAR
2024-05-31 ARVN Grant (A) +5,899 $0 EDGAR
2024-04-09 Astria Therapeutics, Inc. (ATXS) Delisted Grant (A) — $0 EDGAR
2023-06-20 ARVN Grant (A) +8,242 $0 EDGAR
2022-06-03 Calithera Biosciences, Inc. (CALA) Delisted Grant (A) — $0 EDGAR
2022-03-08 SANA Grant (A) — $0 EDGAR
2021-09-17 SANA Sell (S) −60,000 -$1.56M EDGAR
2021-06-14 Calithera Biosciences, Inc. (CALA) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 53
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.